MEDX - ETF AI Analysis
Top Page
Horizon Kinetics Medical ETF (MEDX)
MEDX, the Horizon Kinetics Medical ETF, reflects a solid overall quality driven mainly by large positions in strong, diversified pharma leaders like Eli Lilly and Merck, which benefit from robust financial performance, positive earnings outlooks, and strategic pipelines. Additional support comes from holdings such as Novartis, Johnson & Johnson, AstraZeneca, Alkermes, and Bristol-Myers Squibb, which together add innovation and growth potential but also introduce risks around high valuations, debt levels, and product or revenue challenges. The main risk factor is the ETF’s concentration in a single sector—large pharmaceutical and biotech companies—where issues like leverage, overvaluation, and regulatory or product setbacks can affect many holdings at once.
MEDX vs. SPDR S&P 500 ETF (SPY)
- AUM
- 17.76M
- Region
- Global
- Expense Ratio
- 0.85%
- Beta
- 0.44
- Issuer
- Horizon Kinetics
- Inception Date
- Jan 30, 2023
- Dividend Yield
- 1.07%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
MEDX Summary
MEDX, the Horizon Kinetics Medical ETF, focuses on the health care theme rather than tracking a specific index. It invests mainly in U.S. health care companies across areas like biotech, drug makers, medical devices, and health care services. Well-known holdings include Eli Lilly and Johnson & Johnson, along with other major pharmaceutical names. Someone might invest in MEDX to get broad, one-stop exposure to the long-term growth potential of the medical and health care industry. A key risk is that it is heavily concentrated in health care stocks, so its value can rise or fall sharply with changes in that sector.
How much will it cost me?
This ETF has an expense ratio of 0.85%, which means you’ll pay about $8.50 per year for every $1,000 invested. That’s higher than the average ETF because it’s more specialized and actively managed within the health care sector, which typically costs more to run.
What would affect this ETF?
MEDX could benefit from global aging populations, growing demand for medical treatments, and successful new drugs or technologies from major holdings like Eli Lilly, AbbVie, and other large pharmaceutical and biotech companies. On the downside, tighter health care regulations, government efforts to control drug prices, patent expirations, or economic slowdowns that pressure health care budgets around the world could hurt the fund’s future performance.
MEDX Top 10 Holdings
MEDX is leaning heavily on a handful of big drugmakers, with Eli Lilly and AbbVie doing much of the heavy lifting as their shares keep rising on strong pipelines and upbeat earnings. Amgen and Biogen add more fuel, showing solid, momentum-driven gains that help power the fund. On the flip side, AstraZeneca has been lagging, acting like a small anchor on an otherwise strong health care ship, while Bristol-Myers looks more mixed. Overall, it’s a globally diversified bet on large, innovative pharma and biotech names.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 LLY | Eli Lilly & Co | 20.93% | $3.76M | $1.33T | 63.52% | 72Outperform |
 ABBV | AbbVie | 9.95% | $1.79M | $521.11B | 32.47% | 66Neutral |
 NVS | Novartis | 6.78% | $1.22M | $298.74B | 30.48% | 80Outperform |
 JNJ | Johnson & Johnson | 5.77% | $1.04M | $657.68B | 43.25% | 78Outperform |
 AMGN | Amgen | 4.83% | $868.64K | $251.94B | 55.97% | 77Outperform |
 ALKS | Alkermes | 4.59% | $825.10K | $7.61B | 46.22% | 80Outperform |
 AZN | AstraZeneca | ― | ― | ― | ― | 80Outperform |
 MRK | Merck & Company | 4.41% | $793.65K | $368.89B | 72.55% | 80Outperform |
 BMY | Bristol-Myers Squibb | 4.15% | $745.76K | $127.71B | 36.79% | 78Outperform |
 BIIB | Biogen | 3.48% | $624.92K | $37.49B | 61.41% | 74Outperform |
MEDX Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For MEDX, the sentiment is Positive. The current price of 38.07 is above the 20-day moving average (MA) of 36.23, above the 50-day MA of 36.00, and above the 200-day MA of 34.67, indicating a bullish trend. The MACD of 0.62 indicates Negative momentum. The RSI at 68.04 is Neutral, neither overbought nor oversold. The STOCH value of 81.52 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MEDX.
MEDX Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| MEDX | $38.07 | $39.00(2.44% Upside) | $17.76M | 0.85% | 65Neutral |
 FMED | $31.54 | $42.77(35.58% Upside) | $54.39M | 0.50% | 59Neutral |
 MEDI | $34.97 | $45.39(29.78% Upside) | $45.79M | 0.80% | 62Neutral |
 TMED | $34.13 | $56.68(66.05% Upside) | $34.83M | 0.44% | 61Neutral |
 BMED | $36.10 | $39.55(9.55% Upside) | $14.58M | 0.55% | 65Neutral |
 HLTH | $27.56 | $36.92(33.96% Upside) | $12.63M | 0.75% | 55Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MEDX | Horizon Kinetics Medical ETF | 38.07 | 7.41 | 24.19% | |
| FMED | Fidelity Disruptive Medicine ETF | 31.54 | 5.54 | 21.29% | |
| MEDI | Harbor Health Care ETF | 34.97 | 4.87 | 16.19% | |
| TMED | T. Rowe Price Health Care ETF | 34.13 | 5.78 | 20.39% | |
| BMED | Future Health ETF | 36.10 | 8.00 | 28.46% | |
| HLTH | Tema Healthcare AI ETF | 27.56 | 2.25 | 8.89% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.